We serve Chemical Name:1-methylpyrido[1,2-a]benzimidazol-8-ol CAS:501447-52-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![1-methylpyrido[1,2-a]benzimidazol-8-ol](https://a.dearchem.com/CAS2/501447-52-5.png)
Chemical Name:1-methylpyrido[1,2-a]benzimidazol-8-ol
CAS.NO:501447-52-5
Synonyms:1-methylpyrido[1,2-a]benzimidazol-8-ol
Molecular Formula:C12H10N2O
Molecular Weight:198.22100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:37.53000
Exact Mass:198.07900
LogP:2.50150
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1-methylpyrido[1,2-a]benzimidazol-8-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-methylpyrido[1,2-a]benzimidazol-8-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-methylpyrido[1,2-a]benzimidazol-8-ol Use and application,1-methylpyrido[1,2-a]benzimidazol-8-ol technical grade,usp/ep/jp grade.
Related News: So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. 5-(3,4-difluorophenyl)-7-methyl-5,6,7,8-tetrahydrofuro[3,2-g]isoquinoline hydrochloride manufacturers This not only makes it easier to remove enzyme residues from the desired product, but also ensures valuable high turnover enzymes can be reused multiple times without compromising their activity. Pyridazine, hexahydro-3-methyl-1-phenyl-6-[(phenylseleno)methyl]-, cis- suppliers So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. Pyrrolo[1,2-a]pyrazin-4(3H)-one, 1-ethoxy-6,7,8,8a-tetrahydro-, (S)- vendor & factory Patients having Zynteglo treatment for beta thalassaemia also need conditioning treatment to clear out their bone marrow cells before receiving Zynteglo. Healthcare professionals should therefore explicitly inform patients receiving Zynteglo of the increased risk of blood cancers from medicines used in conditioning treatments.,Wavelength, a more than 30-year-old firm based in Petah Tikva, launched its API CDMO business in early 2020 and currently sports more than 250 customers from 50 countries.
